Randomized, open-label, phase 2 study of SAR408701 combined with pembrolizumab and pembrolizumab alone in patients with CEACAM5 and PD-L1 positive advanced/metastatic non-squamous non–small-cell lung cancer (NSQ NSCLC)

  • Park, John (Primary Chief Investigator)
  • Chapman, Nicola (Clinical Trial Unit Staff)

Project: Research

Project Details

AcronymACT16146
StatusActive
Effective start/end date14/08/20 → 1/07/25